Considering that USP7 is a crucial regulator of the MDM2/MDMX-p53 pathway, its impact on cancer progression and survival has been demonstrated to be linked to the stabilization of MDM2 and MDMX in different tumors such as neuroblastoma (NB) [74], glioma [61], multiple myeloma [58], epithelial ovarian cancer [59], and both lung squamous cell carcinoma and large cell carcinoma [75]. This evidence concerns the gene MDM2 and plasma cell myeloma.